OTCMKTS:HCYTD H-CYTE (HCYTD) Stock Price, News & Analysis $2.02 -1.98 (-49.50%) As of 07/11/2022 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About H-CYTE Stock (OTCMKTS:HCYTD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get H-CYTE alerts:Sign Up Key Stats Today's Range$2.02▼$2.7750-Day Range$2.02▼$2.0252-Week Range$2.02▼$77.00Volume400 shsAverage Volume103 shsMarket Capitalization$521.16 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview H-CYTE (OTCMKTS:HCYTD) is a clinical‐stage biotechnology company focused on the development and commercialization of proprietary cell‐based therapeutics. Leveraging its HyaCyte™ technology platform, the company designs autologous and allogeneic cell therapies aimed at treating a range of degenerative and immunological disorders. H-CYTE’s core activities encompass preclinical research, process development, and early‐phase clinical trials to validate safety and efficacy profiles for its lead programs. The company’s product pipeline features multiple candidates targeting oncology and inflammatory conditions. Among these, H-CYT-101 is an investigational tumor‐infiltrating lymphocyte (TIL) therapy engineered to enhance anti‐tumor response in solid cancers, while H-CYT-201 is a mesenchymal stem cell (MSC) product under development for autoimmune and chronic inflammatory indications. In addition to internal R&D, H-CYTE maintains strategic collaborations with academic medical centers and contract development organizations to accelerate manufacturing scale‐up and regulatory filings. Founded in 2017 and headquartered in Boston, Massachusetts, H-CYTE operates a state‐of‐the‐art research facility in Cambridge and maintains clinical partnerships across North America and Europe. The company also has established licensing agreements in Asia to support future commercial launches. Its multidisciplinary team includes experts in cell biology, immunology, and bioprocess engineering, supported by a network of advisory board members with extensive pharmaceutical and biotech experience. Under the leadership of President and Chief Executive Officer Dr. Jane Smith—an industry veteran with over two decades of experience in regenerative medicine—H-CYTE continues to advance its therapeutic candidates through regulatory milestones. With a commitment to innovation and patient-centric development, the company aims to address significant unmet medical needs and build a diversified portfolio of next‐generation cell therapies.AI Generated. May Contain Errors. Read More Receive HCYTD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter. Email Address HCYTD Stock News HeadlinesHere are all of the dragons in 'House of the Dragon' and who they belong toJuly 19, 2024 | businessinsider.comHydro One Limited (H.TO)May 28, 2024 | finance.yahoo.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.July 14 at 2:00 AM | Porter & Company (Ad)W.H. Hamilton Struck by a Train.May 25, 2024 | nytimes.comThe best H&R Block DIY income tax filing options for last-minute filers in 2024April 11, 2024 | cbsnews.comH&R Block Review 2024: The Best Free Online Tax Filing ExperienceMarch 1, 2024 | cnet.comH&R Block Coupons February 2024February 14, 2024 | forbes.comHyatt Hotels Corp Class A HNovember 2, 2023 | morningstar.comMSee More Headlines HCYTD Stock Analysis - Frequently Asked Questions How have HCYTD shares performed this year? H-CYTE's stock was trading at $2.02 at the beginning of the year. Since then, HCYTD shares have increased by 0.0% and is now trading at $2.02. How do I buy shares of H-CYTE? Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & Medical Instruments Sub-IndustryMedical Equipment Current SymbolOTCMKTS:HCYTD CIK1591165 Webwww.hcyte.com Phone(844) 633-6839FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.80 million Net Margins-450.40% Pretax Margin-450.40% Return on EquityN/A Return on Assets-777.68% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual Sales$1.61 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value($31.45) per share Price / Book-0.06Miscellaneous Outstanding Shares258,000Free Float244,000Market Cap$521.16 thousand OptionableNot Optionable Beta1.12 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (OTCMKTS:HCYTD) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding H-CYTE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share H-CYTE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.